PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ergocalciferol→

Ergocalciferol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
50-14-6
Molecular formula
C28H44O
Molecular weight
396.6 g/mol
Drug class
Vitamin D2fat-soluble vitamin and prohormone
Mechanism of action
Converted in the liver to 25-hydroxyvitamin D2 and subsequently in the kidney to active 1,25-dihydroxyvitamin D2, which activates the vitamin D receptor and regulates calcium and phosphate homeostasis.
Indications / reported uses
  • Prevention and treatment of vitamin D deficiency and nutritional rickets
  • Treatment of hypoparathyroidism-associated hypocalcaemia and selected phosphate-wasting disorders where appropriate; dosing depends on the formulation and clinical monitoring

Sources: NIH Office of Dietary Supplements — Vitamin D fact sheet · US DailyMed — Ergocalciferol · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ergocalciferol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ergocalciferol Permitted Daily Exposure (PDE) report (the Ergocalciferol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ergocalciferol Occupational Exposure Limit (OEL) report (the Ergocalciferol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.